Alle Infos zum eBook verschenken
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Hier können Sie sich einloggen
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
The ESC Textbook of Thrombosis is the third iteration of Therapeutic Advances in Thrombosis. Now a new addition to the European Society of Cardiology (ESC) publications portfolio, it is informed by the work of the ESC's Working Group on Thrombosis. Written by internationally renowned experts in the field of thrombosis, the textbook presents an up-to-date and in-depth review of all aspects of thrombosis and antithrombotic therapies. Not only does it reflect contemporary European guidelines from the ESC but also it also summarizes the latest evidence from clinical trials. Covering the topic in…mehr
- Geräte: PC
- mit Kopierschutz
- eBook Hilfe
- Größe: 42.58MB
- The ESC Textbook of Vascular Biology (eBook, PDF)111,95 €
- The ESC Textbook of Cardiovascular Development (eBook, PDF)100,95 €
- The ESC Handbook of Preventive Cardiology (eBook, PDF)30,95 €
- ESC Textbook of Cardiovascular Nursing (eBook, PDF)43,95 €
- The ESC Textbook of Preventive Cardiology (eBook, PDF)111,95 €
- Raffaele De CaterinaThe ESC Textbook of Thrombosis (eBook, ePUB)110,95 €
- The ESC Handbook on Cardiovascular Pharmacotherapy (eBook, PDF)46,95 €
-
-
-
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
- Produktdetails
- Verlag: Oxford University Press
- Seitenzahl: 464
- Erscheinungstermin: 7. Oktober 2023
- Englisch
- ISBN-13: 9780192695925
- Artikelnr.: 69092713
- Verlag: Oxford University Press
- Seitenzahl: 464
- Erscheinungstermin: 7. Oktober 2023
- Englisch
- ISBN-13: 9780192695925
- Artikelnr.: 69092713
Kristensen: Introduction
* Section 1: Pathophysiology of thrombosis
* 2: Lina Badimon and Gemma Vilahur: Arterial thrombosis:
Pathophysiological background
* 3: Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van
Es: Venous thrombosis and thromboembolism: Pathophysiological
background
* 4: Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip: Thrombosis
and thromboembolism in atrial fibrillation: Pathophysiological
background
* 5: Tobias Geisler: Thrombosis on foreign surfaces and devices
* Section 2: Clinical pharmacology of antithrombotic drugs
* 6: Carlo Patrono and Bianca Rocca: Aspirin
* 7: Manan Pareek and Deepak L. Bhatt: Platelet P2Y12 inhibitors
* 8: Luis Ortega-Paz and Dominick Angiolillo: Dipyridamole, cilostazol,
GP IIb/IIIa inhibitors, and PAR-1 antagonists
* 9: Renske Olie and Hugo ten Cate: Heparins, fondaparinux, hirudin,
bivalirudin, argatroban and danaparoid
* 10: Freek W.A. Verheugt and Marc Brouwer: Vitamin K antagonists
* 11: Alex Benz and Stefan Hohnloser: Dabigatran
* 12: Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan
Wallen: Oral factor Xa (FXa) inhibitors
* 13: James C. Fredenburgh and Jeffrey I. Weitz: Forthcoming oral
factor XIa and FXIIa inhibitors
* 14: Peter R Sinnaeve and Frans Van de Werf: Thrombolytic therapy and
ancillary antithrombotic therapies
* Section 3: Therapeutic strategies
* 15: Raffaele De Caterina, Paul M Ridker, and Erica Michelotti:
Antithrombotic strategies in primary cardiovascular prevention
* 16: Antonio Greco and Davide Capodanno: Antithrombotic strategies in
patients undergoing elective percutaneous coronary interventions and
in chronic coronary syndromes without interventions
* 17: William A. E. Parker, Raffaele De Caterina, David J. Moliterno,
Steen Dalby Kristensen and Robert F. Storey: Antithrombotic therapy
in ST-elevation acute myocardial infarction and non-ST elevation
acute coronary syndromes
* 18: Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno:
Anti-thrombotic therapy for patients with prosthetic valves and
during structural percutaneous interventions
* 19: Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom:
Antithrombotic therapies in ischaemic stroke
* 20: Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and
Erik Lerkevang Grove: Antithrombotic therapy in patients with patent
foramen ovale (PFO), PFO closure, left ventricular mural thrombus,
atrial thrombus, and catheter-related thrombosis
* 21: Raffaele De Caterina and Rossella Marcucci: Atrial fibrillation:
current and forthcoming antithrombotic therapies
* 22: Chaozer Er, Walter Ageno, and Ander Cohen: Venous
thromboembolism: prophylaxis and treatment
* 23: Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbäck:
Biomarker-based risk stratification in cardiovascular disease
* Section 4: Special situations
* 24: Vittorio Pengo and Gentian Denas: Antithrombotic therapies in
inherited or acquired thrombophilia
* 25: Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao:
Prevention and treatment of bleeding related to antithrombotic drug
treatment
* 26: Michael Maeng, Steen Dalby Kristensen, and Jolanta M.
Siller-Matula: Management of patients treated with antithrombotic
drugs undergoing surgery
* 27: Alexander C Fanaroff, Renato D Lopes, John H Alexander:
Antithrombotic therapy in patients with atrial fibrillation and
recent coronary stenting, with or without an acute coronary syndrome
* 28: Stefan Agewall, Vanessa Roldán, and Francisco Marín: Prevention
and treatment of venous and arterial thrombosis in patients with
specific conditions: diabetes, renal insufficiency, thrombophilia and
pregnancy
* 29: Steven P. Dunn, Craig J. Beavers, and David J. Moliterno:
Antithrombotic agents and drug-drug interactions
* 30: Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and
Konstantinos D. Rizas: Personalised antithrombotic therapy: Measuring
individual variation and monitoring
* 31: Serge Korjian, Yazan Daaboul, and C. Michael Gibson: Drug
development, clinical trials, and regulatory requirements
Kristensen: Introduction
* Section 1: Pathophysiology of thrombosis
* 2: Lina Badimon and Gemma Vilahur: Arterial thrombosis:
Pathophysiological background
* 3: Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van
Es: Venous thrombosis and thromboembolism: Pathophysiological
background
* 4: Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip: Thrombosis
and thromboembolism in atrial fibrillation: Pathophysiological
background
* 5: Tobias Geisler: Thrombosis on foreign surfaces and devices
* Section 2: Clinical pharmacology of antithrombotic drugs
* 6: Carlo Patrono and Bianca Rocca: Aspirin
* 7: Manan Pareek and Deepak L. Bhatt: Platelet P2Y12 inhibitors
* 8: Luis Ortega-Paz and Dominick Angiolillo: Dipyridamole, cilostazol,
GP IIb/IIIa inhibitors, and PAR-1 antagonists
* 9: Renske Olie and Hugo ten Cate: Heparins, fondaparinux, hirudin,
bivalirudin, argatroban and danaparoid
* 10: Freek W.A. Verheugt and Marc Brouwer: Vitamin K antagonists
* 11: Alex Benz and Stefan Hohnloser: Dabigatran
* 12: Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan
Wallen: Oral factor Xa (FXa) inhibitors
* 13: James C. Fredenburgh and Jeffrey I. Weitz: Forthcoming oral
factor XIa and FXIIa inhibitors
* 14: Peter R Sinnaeve and Frans Van de Werf: Thrombolytic therapy and
ancillary antithrombotic therapies
* Section 3: Therapeutic strategies
* 15: Raffaele De Caterina, Paul M Ridker, and Erica Michelotti:
Antithrombotic strategies in primary cardiovascular prevention
* 16: Antonio Greco and Davide Capodanno: Antithrombotic strategies in
patients undergoing elective percutaneous coronary interventions and
in chronic coronary syndromes without interventions
* 17: William A. E. Parker, Raffaele De Caterina, David J. Moliterno,
Steen Dalby Kristensen and Robert F. Storey: Antithrombotic therapy
in ST-elevation acute myocardial infarction and non-ST elevation
acute coronary syndromes
* 18: Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno:
Anti-thrombotic therapy for patients with prosthetic valves and
during structural percutaneous interventions
* 19: Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom:
Antithrombotic therapies in ischaemic stroke
* 20: Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and
Erik Lerkevang Grove: Antithrombotic therapy in patients with patent
foramen ovale (PFO), PFO closure, left ventricular mural thrombus,
atrial thrombus, and catheter-related thrombosis
* 21: Raffaele De Caterina and Rossella Marcucci: Atrial fibrillation:
current and forthcoming antithrombotic therapies
* 22: Chaozer Er, Walter Ageno, and Ander Cohen: Venous
thromboembolism: prophylaxis and treatment
* 23: Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbäck:
Biomarker-based risk stratification in cardiovascular disease
* Section 4: Special situations
* 24: Vittorio Pengo and Gentian Denas: Antithrombotic therapies in
inherited or acquired thrombophilia
* 25: Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao:
Prevention and treatment of bleeding related to antithrombotic drug
treatment
* 26: Michael Maeng, Steen Dalby Kristensen, and Jolanta M.
Siller-Matula: Management of patients treated with antithrombotic
drugs undergoing surgery
* 27: Alexander C Fanaroff, Renato D Lopes, John H Alexander:
Antithrombotic therapy in patients with atrial fibrillation and
recent coronary stenting, with or without an acute coronary syndrome
* 28: Stefan Agewall, Vanessa Roldán, and Francisco Marín: Prevention
and treatment of venous and arterial thrombosis in patients with
specific conditions: diabetes, renal insufficiency, thrombophilia and
pregnancy
* 29: Steven P. Dunn, Craig J. Beavers, and David J. Moliterno:
Antithrombotic agents and drug-drug interactions
* 30: Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and
Konstantinos D. Rizas: Personalised antithrombotic therapy: Measuring
individual variation and monitoring
* 31: Serge Korjian, Yazan Daaboul, and C. Michael Gibson: Drug
development, clinical trials, and regulatory requirements